Back
Full-text
Journal article

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.

  • McLornan DP Comprehensive Cancer Centre, Division of Haematology, King's College, London.
  • Szydlo R Hammersmith Hospital NHS Foundation Trust, London, United Kingdom.
  • Robin M Service d'Hématologie-Greffe, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France.
  • van Biezen A EBMT Data Office, University Medical Centre, Leiden, the Netherlands.
  • Koster L EBMT Data Office, University Medical Centre, Leiden, the Netherlands.
  • Blok HJP EBMT Data Office, University Medical Centre, Leiden, the Netherlands.
  • Van Lint MT Ospedale San Martino, Genova, Italy.
  • Finke J University of Freiburg, Freiburg, Germany.
  • Vitek A Institute of Haematology and Blood Transfusion, Prague, Czech Republic.
  • Carlson K University Hospital Uppsala, Uppsala, Sweden.
  • Griskevicius L Haematology, Oncology& Transfusion Centre, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
  • Holler E Department of Haematology and Oncology, University of Regensburg, Regensburg, Germany.
  • Itälä-Remes M Stem Cell Transplant Unit, Turku University Hospital, Turku, Finland.
  • Schaap M Department of Haematology, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Socié G Service d'Hématologie-Greffe, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France.
  • Bay JO Service d'hématologie clinique Adulte et pédiatrie, CHU ESTAING, Clermont, France.
  • Beguin Y Department of Haematology, University of Liege, Liege, Belgium.
  • Bruno B A.O.U Citta della Salute e della Scienza di Torino, S.S.C.V.D Trapianto di Cellule Staminali, Torino, Italy.
  • Cornelissen JJ Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands.
  • Gedde-Dahl T Clinic for Cancer, Surgery and Transplantation, Oslo University Hospital, Rikshospitalet, Norway.
  • Ljungman P Department of Haematology, Karolinska University Hospital, Stockholm, Sweden.
  • Rubio MT Department of Haematology, Hopital d`Enfants, Nancy, France.
  • Yakoub-Agha I CHU de Lille, LIRIC, INSERM U995, Universite de Lille, Lille, France.
  • Klyuchnikov E University Hospital Eppendorf, Hamburg, Germany.
  • Olavarria E Hammersmith Hospital NHS Foundation Trust, London, United Kingdom.
  • Chalandon Y Division of Haematology, Geneva University Hospitals, Geneva, Switzerland.
  • Kröger N University Hospital Eppendorf, Hamburg, Germany.
Show more…
  • 2018-05-30
Published in:
  • British journal of haematology. - 2018
JAK inhibitors
allogeneic stem cell transplant
fibrosis
mylelofibrosis
relapse
Adult
Disease Management
Drug Therapy
Female
Hematopoietic Stem Cell Transplantation
Humans
Lymphocyte Transfusion
Male
Middle Aged
Primary Myelofibrosis
Recurrence
Retrospective Studies
Survival Analysis
Transplantation, Homologous
Treatment Outcome
English Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/252852
Statistics
Document views: 29 File downloads:
  • Full-text: 0